Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Complete Response Letter
Biotech
Aldeyra forewarns potential FDA rejection for dry eye med
Aldyera's shares fell more than 60% after the biotech indicated the FDA could soon reject its dry eye disease med due to a lack of convincing data.
Max Bayer
Oct 16, 2023 2:49pm
Second layoff wave hits ImmunityBio in less than a year
Sep 22, 2023 11:22am
Galera lays off 70% as radiotherapy complication drug rejected
Aug 10, 2023 8:19am
2nd time unlucky for Mesoblast as FDA rejects cell therapy
Aug 4, 2023 8:17am
FDA stalls F2G's plans to get new class of antifungal to market
Jun 20, 2023 9:30am
Byondis breast cancer drug fails to bloom as FDA denies approval
May 16, 2023 8:28pm